A large natural experiment study in Ontario, Canada, found that receiving the live attenuated herpes zoster vaccine significantly reduced the risk of a new dementia diagnosis by approximately 18% in adults aged 70 and older, providing the strongest evidence to date for a potential causal protective effect. The research leveraged a policy threshold where public funding for the vaccine was determined by birthdate (on or before January 1, 1946, or 1945), comparing the health outcomes of nearly identical groups born immediately on either side of this cutoff. Those eligible for vaccination had an absolute reduction in dementia risk of 2.0 percentage points over a 5.5-year follow-up period. The findings were further strengthened by a cross-province comparison showing that eligible birth cohorts in Ontario had significantly lower dementia incidence after the vaccination program began than matched cohorts in provinces without such a program. This evidence points to a promising public health strategy and suggests that investigating the neuroimmune mechanisms involved could offer new insights into dementia pathophysiology. Source: https://www.thelancet.com/
A rigorous cohort study utilizing Taiwan’s National Health Insurance Database provides robust evidence that SGLT2…
A new study investigating the link between cerebral microbleeds (CMBs) and dementia has found that…
A comprehensive prospective study tracking over 159,000 adults for up to three decades has provided…
A comprehensive new Cochrane review of 22 studies involving nearly 2,000 participants over six months…
A large-scale study involving 103,649 UK Biobank participants has revealed that adhering to healthy dietary…
To address uncertainties in statin safety profiles, which are often based on observational data susceptible…
This website uses cookies.